▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025

#AI--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies f...

Immagine

LONDON: #AI--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE).

Poster Presentation Details

Title

Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity

Date and time

Wednesday, December 10, 2025, 08:00 (GMT)

Poster number

309P

Location

The Churchill Room, Queen Elizabeth II Centre, London

Bispecific TCE Overview

For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA™, was used to discover and concomitantly optimise a TCE with improved killing selectivity, potency, efficacy, and manufacturability. The biological mechanism underlying this enhanced selectivity is based on the principle of avidity. By harnessing avidity-driven selectivity, the optimised TCE can distinguish between healthy and diseased cells based on differential tumour-associated antigen expression.

About LabGenius Therapeutics

LabGenius Therapeutics is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius Therapeutics operates a hybrid business model that includes partnering with biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline. For more information, please visit www.labgeniustx.com, or connect on LinkedIn.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

MathWorks Showcases AI for Safety-Critical Systems at NeurIPS 2025

NeurIPS 2025, Booth #732 – MathWorks, the leading developer of mathematical computing software, will showcase how engineers and scientists can use MATLAB®…

CORRECTING and REPLACING Block Processes 124 Million Transactions as Americans…

In Lower West Side, Chicago section, first bullet point should read: Total BFCM Weekend Volume: $8.4M (instead of Total BFCM Weekend Volume: $49M). The…

Palantir Launches Chain Reaction to Build American AI Infrastructure;…

Palantir Technologies Inc. (NASDAQ: PLTR) today unveiled Chain Reaction, the operating system for American AI infrastructure. The bottleneck to AI innovation…

Andersen Consulting Expands Presence Through Collaboration with Hilal…

#AndersenConsulting--Andersen Consulting enters into a Collaboration Agreement with Hilal Technology to strengthen its capabilities in digital infrastructure,…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!